Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Hydroxyurea: A Treatment Option for Sickle Cell Disease
source: Sickle Options
year: N/A
summary/abstract:Hydroxyurea is a chemotherapy drug used to treat cancer and blood diseases particularly in the conditions such as polycythemia vera (increased number of red blood cells), essential thrombocytosis (increased number of platelets) and sickle cell disease. It is the only drug approved by the Food and Drug Administration (FDA) to treat sickle cell disease. It works by increasing the levels of fetal hemoglobin (HbF) in Red Blood Cells (RBC) which allows the RBCs to be more flexible and slippery and makes it harder for RBCs to form the sickle shape.
Hydroxyurea is available in pill and liquid form. It is usually available in pills of 200 mg, 300 mg, 400 mg and 500 mg dose strength under different brand names. Generic capsules of dose strength 250 mg and 500 mg of Hydroxyurea are also available in market. It is usually covered by insurance.
read more
+myBinderRelated Content
-
Targeted education after an emergency department visit increases hydroxyurea initiation in children with sickle cell...Introduction: Hydroxyurea decreases man...
-
Robust Clinical and Laboratory Response to Hydroxyurea Using Pharmacokinetically Guided Dosing for Young Children Wi...Hydroxyurea is FDA-approved and now incr...
-
Don’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
-
FDA Approves Hydroxyurea Tablets for Pediatric Patients With Sickle Cell AnemiaThe US Food and Drug Administration (FDA...
-
Effort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
Teen with sickle cell disease takes class trip to Europe with Loyola Medicine’s helpAnyah Randolph, a teenager with sickle c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.